The 12 most common partnerships and co-selling mistakes and how to fix them for healthcare and life sciences in the Nordics
Every mistake we see teams make with partnerships and co-selling — starting with the ones that cost the most and are the cheapest to fix. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Nordics.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Nordics. In this market, Nordic buyers reward directness, small buying committees, and a track record over a pitch, so the way you install partnerships and co-selling has to be shaped to that reality from day one.
Every partnerships and co-selling failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.
Mistake one, the foundational one: signing MOUs no one operationalises. Fix by naming an owner and writing kill criteria before you spend a dollar.
Mistake two: mistaking volume for progress. Fix by making sourced and influenced pipeline from partners the only weekly headline number.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Nordics it is compounded by the fact that reputation compounding, not campaign spend is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.
Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.
Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.
Mistake five: ignoring the trigger. Partnerships and co-selling works when one great partner is worth ten marketing hires; without a real trigger the model is guesswork.
Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.
Concretely for healthcare and life sciences in the Nordics: the healthcare teams that install this get past procurement instead of dying in it, and the Nordic teams that install this compound reputation faster than any paid channel could. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Partnerships · healthcare · Nordics — answered
- Does partnerships and co-selling work for healthcare and life sciences in the Nordics?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Nordics, Nordic buyers reward directness, small buying committees, and a track record over a pitch. The healthcare teams that install this get past procurement instead of dying in it.
- What is the most expensive partnerships and co-selling mistake?
- Signing MOUs no one operationalises — because it silently degrades every downstream metric.
- Which mistake is cheapest to fix?
- Missing kill criteria. Write them in an hour and save a quarter of budget.
- Can I skip the quality gate?
- Not in the first four weeks. After the model is proven, you can automate parts of it.
- How do I know a mistake is compounding?
- Sourced and influenced pipeline from partners stalls or drops for two consecutive weeks. That is your alarm.
- What is the Nordics-specific pitfall when running partnerships and co-selling for healthcare?
- Importing a playbook that was built for another market. In the Nordics, Nordic buyers reward directness, small buying committees, and a track record over a pitch — the install has to reflect that.
Growth Broker editorial
Filed under partnerships · healthcare · nordics